CRISPR targeting of mmu-miR-21a through a single adeno-associated virus vector prolongs survival of glioblastoma-bearing mice
Glioblastoma (GB), the most aggressive tumor of the central nervous system (CNS), has poor patient outcomes with limited effective treatments available. MicroRNA-21 (miR-21(a)) is a known oncogene, abundantly expressed in many cancer types. miR-21(a) promotes GB progression, and lack of miR-21(a) reduces the tumorigenic potential. Here, we propose a single adeno-associated virus (AAV) vector strategy targeting mmu-miR-21a using the Staphylococcus aureus Cas9 ortholog (SaCas9) guided by a single-guide RNA (sgRNA). Our results demonstrate that AAV8 is a well-suited AAV serotype to express SaCas9-KKH/sgRNA at the tumor site in an orthotopic GB model. The SaCas9-KKH induced a genomic deletion, resulting in lowered mmu-miR-21a levels in the brain, leading to reduced tumor growth and improved overall survival. In this study, we demonstrated that disruption of genomic mmu-miR-21a with a single AAV vector influenced glioma development, resulting in beneficial anti-tumor outcomes in GB-bearing mice.
Authors
- Erik R. Abels (ORCID: https://orcid.org/0000-0003-0146-3501)
- David Rufino‐Ramos (ORCID: https://orcid.org/0000-0002-5125-9667)
- Koen Breyne (ORCID: https://orcid.org/0000-0002-0713-2407)
- Benjamin P. Kleinstiver (ORCID: https://orcid.org/0000-0002-5469-0655)
- Marike L. D. Broekman (ORCID: https://orcid.org/0000-0002-0226-0119)
- Casey A. Maguire (ORCID: https://orcid.org/0000-0001-8681-5179)
- Lisa Nieland (ORCID: https://orcid.org/0000-0002-4396-8252)
- Anne B. Vrijmoet
- Xandra O. Breakefield
- Isabelle W Jetten
- Alexandra J E M de Reus
Institutions
- Harvard University (US)
- Leiden University Medical Center (NL)
- Massachusetts General Hospital (US)
Publication Details
- Journal
- Molecular Therapy
- Published
- 2024-11-19
- DOI
- https://doi.org/10.1016/j.ymthe.2024.11.023
- Citations
- 6
- Primary Topic
- CRISPR and Genetic Engineering
- Type
- article
- Field-Weighted Citation Impact
- 1.40
Funders
- Friedreich's Ataxia Research Alliance
- Hersenstichting
- National Institutes of Health
- NIH Office of the Director
- National Cancer Institute
- National Institute of Neurological Disorders and Stroke
- Common Fund